PotentantibacterialagentwhichdisruptslipidbilayersynthesisthroughinhibitionofLpxC(IC50=1.1nMinPseudomonasaeruginosa);effectiveagainstarangeofgramnegativebacteria.
SoldforresearchpurposesunderagreementfromPfizerInc.
Thetechnicaldataprovidedaboveisforguidanceonly.ForbatchspecificdatarefertotheCertificateofAnalysis.
AllTocrisproductsareintendedforlaboratoryresearchuseonly.
Thefollowingdataisbasedontheproductmolecularweight412.43.Batchspecificmolecularweightsmayvaryfrombatchtobatchduetosolventofhydration,whichwillaffectthesolventvolumesrequiredtopreparestocksolutions.